Phaseline

Targets › CD155

CD155: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: the race on CD155, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Nectin TherapeuticsNTX-1088
anti-CD155 (PVR) monoclonal antibody
CD155Phase 1CancerDec 2026

Conditions

Cancer (1)

Modalities

mixed (1)

Companies

Nectin Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.